RxDoctor Payments Data

Guillermo Reyes, MD

Cardiovascular Disease · San Antonio, TXNPI 1164544656

Payments from drug & device makers

$15,815in general payments, 2019–2025

Across 662 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • Johnson & Johnson$2K
  • Bard Peripheral Vascular, Inc.$2K
  • Scpharmaceuticals Inc.$977
  • Abbott$824
  • Sanofi-aventis U.S. LLC$661
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$15,35197%
  • Education$4643%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,815 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$796,078
Medicare patients
352
Services billed
4,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban143$178,238
EliquisApixaban109$145,642
EntrestoSacubitril/Valsartan22$34,609
BrilintaTicagrelor32$32,035
Repatha SureclickEvolocumab28$23,267
MultaqDronedarone Hcl13$13,327
Nifedipine ErNifedipine173$5,138
ClopidogrelClopidogrel Bisulfate349$3,842
SotalolSotalol Hcl126$3,221
Clonidine17$3,068
Enoxaparin Sodium15$2,990
Atorvastatin Calcium259$2,810
Metoprolol Succinate160$1,980
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,259
Prasugrel Hcl12$1,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$2,398$178,238143 claims
PfizerEliquis$471$145,642109 claims
AstraZenecaBrilinta$433$32,03532 claims
Sanofi-aventis U.S. LLCMultaq$661$13,32713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →